2-((S)-2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethan-1-amine | 1224373-32-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-((S)-2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethan-1-amine
• 英文别名: 2-[(4S)-2,2-bis[(9Z,12Z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-N,N-dimethylethanamine
• CAS: 1224373-32-3
• 化学式: C₄₃H₇₉NO₂
• 分子量: 642.106
• InChiKey: LRFJOIPOPUJUMI-GESJKWTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  15.7
• 重原子数：
  46
• 可旋转键数：
  33
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-((四氢吡喃-2-基)氧基)-1-溴戊烷 在 盐酸 、 氢氧化钾 、 碘 、 sodium carbonate 、 二甲胺 、 三乙胺 、 pyridinium chlorochromate 作用下， 生成 2-((S)-2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethan-1-amine
  参考文献：
  名称：

  IONIZABLE CATIONIC LIPIDS

  摘要：

  本公开提供了可用作离子化阳离子脂质体的化合物。这些离子化阳离子脂质体可用于制备脂质纳米粒子，以将治疗性核酸传递到细胞中。改进了阳离子离子化脂质体的稳定性，以防止在储存过程中发生氧化降解。

  公开号：

  US20220162521A1

文献信息

• METHODS AND COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS
  申请人：Hope Michael J

  公开号：US20130017223A1

  公开（公告）日：2013-01-17

  A lipid particle can include a plurality of cationic lipids, such as a first cationic lipid and a second cationic lipid. The first cationic lipid can be selected on the basis of a first property and the second cationic can be selected on the basis of a second property. The first and second properties are complementary. The attributes of the lipid particle can reflect the selected properties of the cationic lipids, and the complementary nature of those properties.
• [EN] PROCESSES FOR PREPARING LIPIDS<br/>[FR] PROCÉDÉS DE PRÉPARATION DE LIPIDES
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2010048536A2

  公开（公告）日：2010-04-29

  The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic aicd to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific tagrget protein at relatively low doses. The compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
• [EN] IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF<br/>[FR] NANOPARTICULES LIPIDIQUES ET LIPIDES CATIONIQUES IONISABLES, ET LEURS PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION
  申请人：[en]TIDAL THERAPEUTICS, INC.

  公开号：WO2022120388A2

  公开（公告）日：2022-06-09

  Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
• [EN] LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF<br/>[FR] NANOPARTICULES LIPIDIQUES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]AKAGERA MEDICINES, INC.

  公开号：WO2023230587A2

  公开（公告）日：2023-11-30

  The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-di oxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.